

## **NAMs for Improved Chemical &** Product **Safety Assessment**

#### **AN EDUCATION & TRAINING OPPORTUNITY**







**HUMAN-PREDICTIVE** 

**APPROACHES IN TOXICOLOGY** 

**& BIOMEDICAL RESEARCH** 

### **About HSI**





ADVANCING

WORLDWIDE

- $\rightarrow$  HSI represents the largest force for animal protection globally, active on the ground in >60 countries across **Europe, the Americas, Asia & Africa**
- $\rightarrow$  Our science team brings together experts in human & environmental toxicology, risk assessment, biomedicine, law and public policy, etc.
- $\rightarrow$  Working with regulatory authorities, industry, policy-makers, academia and public interest stakeholders
- Accredited stakeholder of ECHA, EFSA, CARACAL, EURL-ECVAM, OECD Test Guidelines & AOP development programmes & other governmental advisory bodies on chemical safety (e.g. US EPA)



→ Any technology, methodology, approach, or combination thereof that can be used to provide information on chemical hazard and risk assessment that avoids the use of intact animals.\*

→ In a broad context, NAMs include in silico approaches, in chemico and in vitro assays, as well as the inclusion of information from the exposure of chemicals in the context of hazard assessment. They also include a variety of new testing tools, such as "high-throughput screening" and "high-content methods" e.g. genomics, proteomics, metabolomics; as well as some "conventional" methods that aim to improve understanding of toxic effects, either through improving toxicokinetic or toxicodynamic

knowledge for substances.<sup>#</sup> \*US EPA – Strategic plan to promote the development and implementation of alternative test methods within the TSCA program. 2018 # ECHA – New Approach methodologies in regulatory science – Proceedings of a scientific workshop. 2016



### **Next-Generation Risk Assessment (NGRA)**



Transparent and explicit about logic of overall approach

#### How the risk assessment should be documented

Dent et al. 2018. Principles underpinning the use of new methodologies in the risk assessment of cosmetic ingredients. Computational Toxicology 7:20-26.

#### Identifying and characterizing sources of uncertainty





### **SEURAT\* Decision Framework**

#### \* SAFETY EVALUATION ULTIMATELY REPLACING ANIMAL TESTING (EU FP7 RESEARCH FLAGSHIP)



(Gavin Maxwell, Paul Carmichael, Unilever. 2019)







### The AFSA Collaboration works to accelerate global adoption of a modern, species-relevant approach to safety assessment that will better protect people and our planet, and hasten the replacement of animal testing

### **5 AFSA workstreams**





**Non-Animal Cosmetic** Safety Assessment & Legislative Reform







Vaccine Global

Regulatory



**Alternatives Databa** 

Harmonization





### Non-animal cosmetic safety assessment

#### Supporting innovation without new animal testing

- Risk-based safety decisions through integration of scientific evidence from  $\rightarrow$ multiple sources
- Exposure-led, product & use-specific, iterative safety decision frameworks  $\rightarrow$
- Sharing of relevant case studies from multiple stakeholders  $\rightarrow$

#### **Developing & disseminating a global training program in next-generation** risk assessment (NGRA)

- Support regional capacity-building to achieve long-term acceptance & implementation of legislative measures
- $\rightarrow$  Address the needs of regulatory & regulated communities, CROs & other stakeholders





### SCOPE

→ Exposure, hazard & risk decision-making approaches without the use of animals

Regulatory & non-regulatory decisions

Collaboration between industry, consultants,
CROs, regulators

→ Development of frameworks & case studies

#### **Target audiences:**

Regulators and industry assessors, including SMEs, safety and regulatory compliance consultants, academic researchers and students



#### **Training modules in development**

- **Problem formulation** (hypothesis generation) 1.
- 2. Consumer exposure (use habits, exposure routes, etc.)
- **3. Predictive chemistry** (read-across, Q/SAR, etc.)
- 4. Exposure-based waiving (TTC)
- **5. Internal exposure** (PBPK, IVIVE)
- 6. In vitro assay synthesis (IATA, defined approaches)
- **Integration into risk assessment** (WoE, MoS 7. determination, etc.)
- History of safe use 8.









#### **Dissemination channels**

- → Lectures & small group trainings
- $\rightarrow$  Webinars
- $\rightarrow$  Videos
- $\rightarrow$  1-pagers
- Continuing education sessions
- → Symposia
- → AFSA website (coming soon)





### INVITATION





HUMANE SOCIETY INTERNATIONA

- **Companies** whose aims are aligned with those of AFSA are invited to join the collaboration
- **Authorities** are invited to provide input in terms of training content (priority modules, anything we've overlooked?) & discuss channels for dissemination
- **Companies** are invited to contribute existing training material for specific AFSA modules, or assist in the creation of new material
- **Partner companies** are invited to discuss legislative language with HSI & affiliates with a view to global harmonisation





# Thank you!

#### Lidia Ceriani, MSc

Regulatory Science Advisor Iceriani@hsi.org

hsi.org

